FY2026 EPS Estimates for CorMedix Raised by HC Wainwright

Key Points

• HC Wainwright raised CorMedix’s FY2026 EPS estimate to $0.54 from $0.51, matching the current analyst consensus. The firm also forecasts EPS of $1.23 for FY2029 and $1.71 for FY2030.
• CorMedix beat quarterly expectations, reporting $0.29 EPS versus the $0.24 consensus and revenue of $101.93 million compared with $96.04 million expected.
• Analyst sentiment remains positive, with six Buy ratings and two Holds producing a “Moderate Buy” consensus and an average price target of $15, versus the stock’s reported $7.54 opening price.

CorMedix Inc (NASDAQ:CRMD - Free Report) - Research analysts at HC Wainwright boosted their FY2026 earnings estimates for CorMedix in a note issued to investors on Friday, August 14th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of $0.54 per share for the year, up from their prior estimate of $0.51. The consensus estimate for CorMedix's current full-year earnings is $0.54 per share. HC Wainwright also issued estimates for CorMedix's FY2029 earnings at $1.23 EPS and FY2030 earnings at $1.71 EPS.

CorMedix (NASDAQ:CRMD - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported $0.29 earnings per share for the quarter, beating analysts' consensus estimates of $0.24 by $0.05. CorMedix had a net margin of 40.49% and a return on equity of 40.52%. The business had revenue of $101.93 million for the quarter, compared to analysts' expectations of $96.04 million.

Several other equities research analysts also recently weighed in on CRMD. Leerink Partners raised their target price on shares of CorMedix from $13.00 to $14.00 and gave the company an "outperform" rating in a research note on Tuesday, April 28th. Royal Bank Of Canada upped their price target on CorMedix from $13.00 to $14.00 and gave the stock an "outperform" rating in a research report on Friday. Zacks Research upgraded CorMedix from a "strong sell" rating to a "hold" rating in a report on Friday, May 15th. Needham & Company LLC raised their price objective on CorMedix from $14.00 to $15.00 and gave the stock a "buy" rating in a research report on Monday, April 27th. Finally, Citizens Jmp restated a "market outperform" rating and set a $19.00 target price on shares of CorMedix in a research note on Tuesday, April 28th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $15.00.

CorMedix Stock Performance

NASDAQ CRMD opened at $7.54 on Monday. The company has a quick ratio of 2.36, a current ratio of 2.56 and a debt-to-equity ratio of 0.31. The firm has a market cap of $587.67 million, a PE ratio of 3.52 and a beta of 1.50. The company has a 50 day moving average price of $8.14 and a 200 day moving average price of $7.65. CorMedix has a 52 week low of $6.13 and a 52 week high of $14.96.

Institutional Trading of CorMedix

A number of institutional investors have recently bought and sold shares of the stock. Financial Management Professionals Inc. acquired a new position in CorMedix during the 4th quarter valued at approximately $25,000. Comerica Bank lifted its stake in shares of CorMedix by 454.6% during the third quarter. Comerica Bank now owns 2,690 shares of the company's stock worth $31,000 after buying an additional 2,205 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of CorMedix during the second quarter worth $42,000. Kestra Advisory Services LLC purchased a new stake in shares of CorMedix during the fourth quarter valued at $49,000. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of CorMedix by 666.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 4,385 shares of the company's stock valued at $51,000 after buying an additional 3,813 shares during the last quarter. 34.18% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about CorMedix

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Q2 results exceeded expectations: CorMedix reported earnings of $0.29 per share versus the $0.28 consensus estimate and revenue of $101.9 million, ahead of expectations near $96.0 million. Net income was $26.0 million and adjusted EBITDA was $58.7 million. CorMedix Second-Quarter Results
• Positive Sentiment: DefenCath and Melinta drove growth: Management cited solid DefenCath utilization and contributions from the Melinta portfolio as key factors behind the revenue beat, supporting the company’s commercial growth story. CRMD Q2 Earnings and Sales Beat
• Positive Sentiment: Profitability outlook improved: CorMedix maintained its fiscal 2026 revenue guidance of $325 million to $345 million, approximately in line with the $334.7 million analyst consensus, while raising its adjusted EBITDA guidance. The company also expects a supplemental filing for its fungal disease treatment by the third quarter, adding a potential pipeline catalyst. CorMedix Supplemental Filing Outlook
• Positive Sentiment: Analyst support strengthened: Royal Bank of Canada raised its price target from $13 to $14 and assigned an “outperform” rating. Other brokerages collectively maintain a “moderate buy” recommendation. RBC Price Target Update
• Neutral Sentiment: Guidance remains broadly aligned with expectations: Although the revenue outlook was maintained rather than raised, the higher EBITDA guidance indicates improving operating leverage and margins. Investors will likely focus on DefenCath adoption and execution against the second-half forecast.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company's lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source